Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.

ABSTRACT:

Objective

To evaluate the efficacy and safety/tolerability of dolutegravir (DTG, S/GSK1349572), a potent inhibitor of HIV integrase, through the full 96 weeks of the SPRING-1 study.

Design

ING112276 (SPRING-1) was a 96-week, randomized, partially blinded, phase IIb dose-ranging study.

Methods

Treatment-naive adults with HIV received DTG 10, 25, or 50 mg once daily or efavirenz (EFV) 600 mg once daily (control arm) combined with investigator-selected dual nucleos(t)ide reverse transcriptase inhibitor backbone regimen (tenofovir/emtricitabine or abacavir/lamivudine). The primary endpoint of the study was the proportion of participants with plasma HIV-1 RNA less than 50 copies/ml, based on time to loss of virologic response at 16 weeks (conducted for the purpose of phase

SUBMITTER: Stellbrink HJ 

PROVIDER: S-EPMC3694319 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature